Biology subjects

Ciarrocchi, A.

Publications and source records attributed to Ciarrocchi, A..

3 recordsLinked to original sources

bioRxiv2026

Waking the sleepers: lincRNA overexpression compromises DHX36 activity and global protein synthesis

Transposable element-derived long intergenic noncoding RNAs (lincRNAs) are increasingly recognized as context-dependent regulators of gene expression; however, the functional consequences of their ectopic activation in somatic cells remain poorly understood. We previously showed that U7 snRNA represses a subset of LTR12-associated lincRNAs, including lnc-ARRDC4-1 and lnc-ADCYAP1-2, two testis-enriched lincRNAs with minimal expression in somatic cells. Here, we examined the consequences of their increased expression in somatic cells. We showed that overexpression of either lincRNA led to common transcriptomic changes, proteomic changes, impaired migration, altered adhesion and proliferation, and a ~50% reduction in protein synthesis. Furthermore, we identified lnc-ARRDC4-1 as an upstream regulator of lnc-ADCYAP1-2 transcription. Downstream of this event, lnc-ADCYAP1-2 interacts with the RNA helicase DHX36, a regulator of G-quadruplex-containing mRNAs. lnc-ADCYAP1-2 activation reduces DHX36 protein levels, which is accompanied by decreased protein output from a subset of DHX36 mRNA targets. At the cellular level, these effects correlate with cellular disfunction and altered global translation. Our results suggest a lnc-ARRDC4-1:lnc-ADCYAP1-2:DHX36 regulatory cascade linking the derepression of LTR12-containing lincRNAs to reduced protein synthesis and altered cellular processes in somatic cells.

Molecular Biology↗

bioRxiv2025

Exploring the mechanism and pattern of bone formation during RANKL inhibition in a mouse model of fibrous dysplasia

Fibrous dysplasia (FD) of bone is a genetic fibro-osseous disorder with increased bone remodeling activity. Inhibition of RANKL modifies FD lesions by inducing the replacement of the fibrous tissue with bone. This effect was observed in FD murine models receiving anti-mouse RANKL antibodies or small molecule RANKL inhibitors and in FD patients treated with denosumab. However, in neither case the mechanism and pattern of deposition of the newly formed bone were clarified. We performed radiographic, morphological and molecular analyses on EF1-GsR201C (FD) mice receiving an anti-mouse RANKL antibody. We observed that RANKL inhibition caused a decrease in the expression of genes involved in osteogenesis, osteoclastogenesis, matrix remodeling and osteoblast-osteoclast cross-talk in affected skeletal segments. Nonetheless, intra-lesional bone surfaces were covered by a continuous layer of osteoid, indicating that bone formation was actively ongoing in the pathological tissue in spite of the treatment. Accordingly, all bone surfaces within FD lesions showed calcein labeling which was never detected in the fibrous tissue far from bone. These results indicate that in the absence of RANKL activity, bone formation in FD tissue does not occur diffusely or stochastically. In contrast, it is restricted to bone surfaces where osteoprogenitor cells are orderly recruited from the adjacent fibrosis, progressively converting it into bone. Clinically, this suggests that the volume of pre-treatment bone in FD lesions may be a determinant of the skeletal improvement that individual patients may achieve during the same denosumab treatment course. As a consequence, it may also be a determinant of the severity of the rebound effect that they can experience upon treatment discontinuation.

pathology↗

bioRxiv2022

Coexisting morpho-biotypes unveil the regulatory bases of phenotypic plasticity in pancreatic ductal adenocarcinoma

Intratumor morphological heterogeneity predicts clinical outcomes of pancreatic ductal adenocarcinoma (PDAC). However, it is only partially understood at the molecular level and devoid of clinical actionability. In this study we set out to determine the gene regulatory networks and expression programs underpinning intra-tumor morphological variation in PDAC. To this aim, we identified and deconvoluted at single cell level the molecular profiles characteristic of morphologically distinguishable clusters of PDAC cells that coexisted in individual tumors. We identified three major morpho-biotypes that co-occurred in various proportions in most PDACs: a glandular biotype with classical epithelial ductal features; a biotype with abortive ductal structures and expressing a partial epithelial-to-mesenchymal transition program; and a poorly differentiated biotype showing partial neuronal lineage priming and absence of both ductal features and basement membrane. The identification of PDAC morpho-biotypes may help improve patient stratification and therapeutic schemes taking into account the spectrum of actionable targets expressed by coexisting tumor components.

cancer biology↗